Toronto, Ontario--(Newsfile Corp. - January 16, 2023) - Leveljump Healthcare Corp. (TSXV: JUMP) (OTCQB: JMPHF) (FSE: 75J) ("Leveljump" or the "Company"), a Canadian leader in B2B telehealth solutions, is pleased to provide a review and update of its advancements in its Action and Business Plans from 2022 and into early 2023.
In February 2022 the Company acquired three IHF's, providing multi-modality imaging to local communities and since that time the Company has been working to modernize operations and increase revenues at the locations. Since acquiring the clinics, the Company has increased revenues, expanded their doctor referral outreach and streamlined workflow processes.
In December 2022, the Company purchased an IHF license in Toronto as well as entered into a lease for a new flagship imaging clinic at the Yonge Sheppard Centre. Design and construction permitting is underway and medical equipment has been ordered. The Company expects this new location to open in the spring of 2023 and increase
In late 2022 the Company entered into an agreement to purchase 4 IHF's in Calgary, Alberta. The Company has engaged a due diligence firm in Calgary and is completing its diligence work shortly. The Company is also working on financing this acquisition with TD Canada Trust. The acquisition is expected to close in the first half of 2023 and increase company revenues by over $4.5 million annually.
During 2022 CTS (the Company's wholly owned operating subsidiary) added additional client hospitals and is working on new client acquisitions for 2023.
During 2022 over $2,700,000 of capital was raised and invested by the Company, leading us to nearly positive adjusted EBITDA. The Company continues to work on financing solutions with its partner TD Canada Trust and seeking new equity partners. Additional capital raised will be directed to additional IHF acquisitions to increase operating revenues and EBITDA.
For 2022 the Company had record revenues and expects 2022 revenues to be 20% higher than 2021.
The Company is expecting to almost double revenues in 2023 as compared to 2022 on a trailing twelve-month basis once the above noted acquisitions are closed and the new IHF centre is operational.
"The last year saw us hit key milestones, growing our business and expanding our impact to provide key healthcare to patients," said, Mitch Geisler, CEO. "Our core business operations continue to perform very well with both telehealth solutions for emergency care and in person clinic services. Over the next year we are focused on strong growth of revenues, ensuring fiscal responsibility with expenses and increasing shareholder value."
The Company also announced today that it has closed on $114,000 of units of (i) one (1) common share of Leveljump ("Common Share"), at an issue price of $0.10 per Common Share; and (ii) one (1) 8% cumulative redeemable convertible Class A Series 1 preferred share ("Preferred Share"), at an issue price of $0.90 per Preferred Share.
Each Preferred Share is non-voting, carries a cumulative annual dividend of 8% payable quarterly, along with a top up dividend of 25% of Leveljump EBITDA above $2,000,000 per year, divided by the then outstanding preferred shares, are redeemable on the fifth anniversary (the "Redemption Date") after issuance at a price of $1.00 per Preferred Share together with all accrued and unpaid dividends, or at a price of $1.10 per Preferred Share if redeemed any time prior to the Redemption Date and are convertible into common shares of the Company at a price of $0.40 per Common Share. Subject to applicable law and to certain exceptions, Leveljump may, at any time prior to the Redemption Date, purchase for cancellation all or any number of the Preferred Shares outstanding from time to time at any price in the open market if they are listed or posted for trading on a stock exchange or by tender available to all of holders of Preferred Shares or by private agreement or otherwise.
About LevelJump Healthcare
LevelJump Healthcare Corp., (TSXV: JUMP) is building a national telehealth medical company and brand, currently by providing teleradiology (remote radiology) services to its client hospitals and imaging centers. Additionally, JUMP owns and operates independent healthcare facilities (IHF's) focused on diagnostic imaging.
ON BEHALF OF THE BOARD OF DIRECTORS OF
LEVELJUMP HEALTHCARE CORP.
Mitchell Geisler, Chief Executive Officer
This email address is being protected from spambots. You need JavaScript enabled to view it.
(833) 840-2020
CAUTIONARY STATEMENT REGARDING FORWARD-LOOKING INFORMATION
This news release contains "forward-looking information" within the meaning of applicable securities laws relating to the Company's business plans and the outlook of the Company's industry. Although the Company believes, in light of the experience of its officers and directors, current conditions and expected future developments and other factors that have been considered appropriate, that the expectations reflected in this forward-looking information are reasonable, undue reliance should not be placed on them because the Company can give no assurance that they will prove to be correct. Actual results and developments may differ materially from those contemplated by these statements. The statements in this press release are made as of the date of this release and the Company assumes no responsibility to update them or revise them to reflect new events or circumstances other than as required by applicable securities laws. The Company undertakes no obligation to comment on analyses, expectations or statements made by third-parties in respect of the Company, Canadian Teleradiology Services, Inc., their securities, or their respective financial or operating results (as applicable).
Neither the Exchange nor its Regulation Services Provider (as that term is defined in the policies of the Exchange) accepts responsibility for the adequacy or accuracy of this release.
The securities being offered have not been, and will not be, registered under the United States Securities Act of 1933, as amended (the "U.S. Securities Act") or any U.S. state securities laws, and may not be offered or sold in the United States or to, or for the account or benefit of, United States persons absent registration or an applicable exemption from the registration requirements of the U.S. Securities Act and applicable U.S. state securities laws. This press release does not constitute an offer to sell or the solicitation of an offer to buy securities in the United States, nor in any other jurisdiction.
Last Trade: | C$0.05 |
Daily Volume: | 0 |
Market Cap: | C$4.820M |
September 03, 2024 August 30, 2024 August 29, 2024 August 28, 2024 |
Recursion Pharmaceuticals is a clinical stage TechBio company leading the space by decoding biology to industrialize drug discovery. Enabling its mission is the Recursion OS, a platform built across diverse technologies that continuously expands one of the world’s largest....
CLICK TO LEARN MOREClearPoint Neuro is a global therapy-enabling platform company providing stereotactic navigation and delivery to the brain. Applications of our ClearPoint Neuro Navigation System include electrode lead placement, placement of catheters, and biopsy. The platform has FDA clearance and is...
CLICK TO LEARN MOREEnd of content
No more pages to load
COPYRIGHT ©2023 HEALTH STOCKS HUB